Tag Archives: entrepreneurship

The Trap of Complacency 

10 Mar

By Karen Deyo, VP of Product, Israel BD, LSN

karen-wp

One message we consistently emphasize when speaking with early-stage companies is the importance of looking beyond your local ecosystem and building relationships with investors globally. Too often, founders assume they have plenty of time to expand their network, particularly in regions that offer strong support for launching startups. 

Paradoxically, those supportive ecosystems can create a false sense of security. Grants, incubators, and local funding programs can make it feel as though capital will always be available. In reality, many regions simply do not have enough follow-on capital to support every company that begins there. When the initial funding runs out, startups may suddenly find themselves approaching a financial cliff. At that point, companies that haven’t built relationships outside their region may be forced to accept unfavorable investment terms just to survive. 

Another common misconception is that companies should only begin speaking with investors once they are actively fundraising. In practice, this approach often backfires. Founders tend to underestimate how long fundraising actually takes—a typical fundraising process can last anywhere from 9 to 18 months. Waiting until the last moment leaves little room to build relationships or refine the company’s strategy. 

Early conversations with investors can be extremely valuable even when a company is not raising capital. Investors bring deep industry knowledge and experience, and their feedback can help companies sharpen their development plans, prioritize critical data, and better understand what will make them investable. Just as importantly, fundraising is ultimately driven by relationships. Building those relationships early can significantly accelerate the process when the time comes to raise capital. 

Rather than treating fundraising as something that switches on and off, companies should think of it more like a dial—one that adjusts the intensity of their efforts over time. Engaging with investors early should be considered just as essential as customer discovery or market research. These conversations can help gauge investor interest, identify potential weaknesses in a strategy, and prevent companies from investing significant time and resources in a direction that may not resonate with the market. 

Sometimes, this early feedback leads to a pivot that ultimately strengthens the company. Making adjustments sooner rather than later can help a startup reach the market faster—or even transform a company that might otherwise fail into one that achieves a successful exit. 

Register for RESI Europe

RESI Europe 2026 Investor Panels Take the Stage in Lisbon 

3 Mar

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation (LSN) is preparing for RESI Europe 2026, taking place March 23 in person at the EPIC SANA Lisboa Hotel, followed by four days of virtual partnering. 

The RESI Europe panel program will bring together active healthcare investors to discuss the sectors and strategies shaping early-stage capital formation across therapeutics, devices, diagnostics, digital health, and enabling technologies. As European companies increasingly look beyond domestic markets for capital, the conversations will reflect cross-border investment dynamics and milestone expectations in today’s disciplined funding environment. 

These panels are structured as constructive dialogue between investors and fundraising CEOs. Attendees will hear directly from venture, corporate, and strategic investors about how opportunities are evaluated, what readiness looks like at Seed and Series A, and how companies can engage the right partnering environments at the right time. 

Join the panelists at RESI Europe 2026 and engage directly with the investors shaping early-stage healthcare capital. 

Special Offer: Register for a RESI Europe 5-day hybrid ticket and receive a complimentary second attendee pass. This promotion applies to standard hybrid registrations and provides an opportunity to bring a colleague to maximize partnering coverage across all five days. 

Register for RESI Europe and secure meetings with active healthcare investors in Lisbon this March. 

Register for RESI Europe
RESI Europe Investor Panel Speakers
Raj-Airey
Raj Airey

Convergence Partners AG
Rosie-Barnett
Rosie Barnett

Delin Ventures
Amine-Benmoussa
Amine Benmoussa

Karista
Marcos-Casado
Marcos Casado

Invivo Partners
Bettina-Ernst
Bettina Ernst

BERNINA BioInvest
Navin-Govind-
Navin Govind

Evidence Ventures

William Hsu

Life Science Angels
Mohammad-Khobreh
Mohammad Khobreh

NG Bio
Carsten-Laue
Carsten Laue

M2Care
Chloe-Lepretre
Chloé Lepretre

Servier
Mukul-Mohanty
Mukul Mohanty

Truffle Capital
Luka-Nicin
Luka Nicin

Pace Ventures
Joseph-Oliver
Joseph Oliver

Stanford Angels of the UK
Soyoung-Park
Soyoung Park

1004 Venture Partners
Francisco-Pinto
Francisco Pinto

Bynd Venture Capital
Bibi-Sattar-Marques
Bibi Sattar Marques

Buenavista Equity Partners
Jeff-Stinson
Jeff Stinson

HTA
Mercedes-Tuin
Mercedes Tuin

Heran Partners
Carmel-van-den-Berk
Carmel van den Berk

Brightlands Venture Partners
Mariette-van-der-Velden
Mariette van der Velden

Curie Capital
Giulia-Vestri
Giulia Vestri

Claris Ventures
Yu-Zhang
Yu Zhang

FaaS Capital

EU Webinar Series: From Discovery to Decision Making Early-Stage Life Science Legible to Capital 

3 Mar

By Greg Mannix, VP, EMEA Business Development, LSN

Life Science Nation’s EU-focused webinar series, From Discovery to Decision: Making Early-Stage Life Science Legible to Capital, continues this week with Session III. Recordings of the first two sessions are available for those who would like to revisit the insights shared by active investors shaping early-stage healthcare financing.

This series examines a central question for early-stage companies: why strong science alone is not enough to secure capital, and how founders can structure development to become legible to investors.

Session I

Why Solid Science Fails to Translate Before Capital Even Considers It

Hosted by Richard Berenson, Managing Partner, Venzyme Catalyst

Watch the recording:
https://youtu.be/ODbukG6cjNM?si=9lj-BGKRhv2wJISW

In Session I, Richard Berenson offered a candid investor perspective on why many early-stage assets stall before diligence begins. He emphasized that the issue is often not a shortage of capital, but a failure of translation.

Scientific merit alone does not make an opportunity investable. Investors must see clarity around risk reduction, defined milestones, regulatory trajectory, and capital deployment strategy. Companies that struggle to articulate this framework may be filtered out long before meaningful evaluation takes place.

The discussion reframed from fundraising challenges as structural alignment issues rather than capital scarcity.

Session II

Legibility, Signal, and the Real Work Between Seed and Series B

Hosted by Karim Galzhar, Partner, OKG Capital

Watch the recording:
https://youtu.be/Dak112sslq4?si=9MpLvecop5Jxw4_E

Session II built on this foundation with a deeper examination of how investors form conviction between Seed and Series B.

Karim Galzhar outlined what global investors require to underwrite early-stage risk. Signals are formed across scientific validation, regulatory planning, commercial strategy, and disciplined capital use. Data alone does not create signals. Structured progress and stage-appropriate positioning.

The session highlighted how companies can unintentionally dilute signals by engaging the wrong forums too early or by misaligning fundraising expectations with development readiness.

Session III — This Wednesday

Partnering Is Not Exposure. It Is Filtration

Wednesday, March 4 | 10:00 AM ET / 4:00 PM CET

Session III will feature Dennis Ford, Founder & CEO of Life Science Nation and creator of the RESI Conference Series, alongside Gregory Mannix, VP, International Business Development, Life Science Nation.

This session confronts a simple truth: great science does not raise capital, signal does. We will examine how investors actually price risk, why fundraising must be run as a disciplined global campaign, and how legibility turns complex science into an investable story.

We will also address a costly mistake: engaging the wrong partnering events and the wrong investors too early. Not every conference, forum, or investor fits every stage of development. Success requires selecting the right venues, building a stage-appropriate global target list, and engaging partners who are structurally aligned with your product. The goal is to replace activity with real transaction momentum.

Registration for Session III is open: https://us02web.zoom.us/webinar/register/WN_oe499TEOQGmrSnoAzNr1yw#/registration

Register for RESI Europe

RESI Europe Partnering Opens March 2: Secure Investor Meetings Early and Bring a Complimentary Second Attendee

24 Feb

By Greg Mannix, VP, EMEA Business Development, LSN

As RESI Europe 2026 approaches, one of the most important milestones is just ahead. On March 2, the partnering platform officially opens, giving registered attendees the opportunity to begin requesting and scheduling meetings with investors, strategic partners, and fellow innovators across the global life science ecosystem.

Below are two key updates to plan around.

Partnering Opens March 2: Secure Meetings Early

Partnering is the foundation of every RESI conference. From the moment the platform opens, companies can review attendee profiles, identify aligned investors and strategic partners, and begin building a focused meeting schedule.

The earlier you register and enter the platform, the more time you can:

  • Refine your profile and messaging
  • Target investors who match your stage and sector
  • Send thoughtful, customized meeting requests
  • Fill your calendar with high-value conversations

RESI Europe is structured to help early-stage companies connect efficiently with active investors. Through curated matchmaking and detailed attendee profiles, startups can prioritize fit over volume. Beyond pre-scheduled 1-to-1 meetings, the conference also creates opportunities for ad hoc introductions and follow-up discussions that often extend well beyond the event itself.

To help attendees prepare, Life Science Nation will host a dedicated RESI Europe Partnering Tutorial on Tuesday, March 3 at 10:00 AM Eastern Time (US and Canada). Understanding the RESI partnering system and using it to its maximum capabilities can make a significant difference in a company’s success at RESI Europe 2026. During this session, LSN staff will walk participants through how to navigate the platform, identify investors and strategic partners who are the best fit, manage outreach effectively, implement a strong follow-up strategy, and leverage the full range of conference content to strengthen their overall partnering experience. You can register for the webinar here.

Complimentary Second Attendee with 5-Day Registration

To help companies maximize their partnering coverage, RESI Europe 2026 is offering a complimentary second attendee pass with a standard 5-day registration.

Bringing a colleague allows your team to:

  • Cover more investor meetings
  • Attend concurrent sessions
  • Expand networking reach across the event
  • Ensure no key conversation is missed

This offer is not valid for Virtual or Audience Access passes. Attendees who registered for a 5-day ticket on or before February 22 may contact salescore@lifesciencenation.com to add a second attendee.

With partnering opening March 2 and expanded registration value now available, now is the time to secure your place. Enter the partnering system early, prepare strategically, and position your company to make the most of RESI Europe 2026.

Register for RESI Europe

RESI Europe and European VC Coalition Seek to Boost EU Biotech Investment 

24 Feb

By Sougato Das, President and COO, LSN

Sougato-Das

RESI Europe is one of the major pieces in the puzzle of how to stimulate biotech and life science investing in Europe. In addition to the largest investor partnering conference coming to Lisbon on March 23, the European Life Sciences Coalition (ELSC), a new alliance of major venture capital firms advocating for increased funding and policy support for Europe’s biotech sector, has launched. The coalition includes leading investors such as Novo Holdings, Sofinnova Partners, Forbion, and Omega Funds, representing a combined €24 billion in life sciences assets and involvement in more than 1,400 companies. It launched in association with Invest Europe, whose 650+ members manage 60% of European private equity and venture capital, totaling €1.25 trillion in assets. Alongside major initiatives like the European Innovation Council, whose funded companies enjoy 50% reimbursement for attending RESI Europe, the ELSC hopes to bring new energy to the entrepreneurial sector of life sciences. 

Despite Europe’s strong pharmaceutical presence—five of the world’s top 10 pharma companies by revenue are European—and the industry supporting 29 million EU jobs, the region struggles to scale and retain biotech and life science innovation. The coalition highlights several challenges: 

  • Fragmented capital markets 
  • Declining numbers of specialized VC firms 
  • Regulatory hurdles 
  • Limited access to growth capital 

Europe accounts for only 7% of global venture capital, compared to 63% for the U.S. and 14% for China. Fortunately, events like RESI Europe create a forum where nearly all of the firms representing the 7% are available for partnering, acting as a facilitator to stimulate European life science investment. The dire need for this is underscored by the fact that nearly all EU-based biotechs that went public last year chose to list outside the EU, highlighting concerns about capital flight. 

ELSC members joined the coalition to help reverse these trends, emphasizing the need for sustained funding from both public and private sources across all stages of life sciences development. Industry leaders argue that Europe must increase investment in innovative medicines and treatments, and create supportive policy frameworks and forums, like RESI Europe, or risk losing access to cutting-edge therapies. The ELSC aims to work with policymakers and leverage Invest Europe’s network to strengthen Europe’s ability to fund and scale biotech innovation domestically.

Register for RESI Europe

Webinar to Fundraising Strategy: Preparing CEOs for RESI Europe and Beyond

24 Feb

By Karen Deyo, VP of Product, Israel BD, LSN

karen-wp

As companies prepare for RESI Europe, preparation begins well before partnering opens. 

Life Science Nation is currently preparing private webinars for members of BioIndustry Park and members of the European Innovation Council. LSN is also available to schedule customized sessions for tech hubs, incubators, accelerators, and ecosystem partners interested in bringing this programming directly to their members. 

The following sessions are structured webinars designed to help early-stage CEOs strengthen the core components of capital formation. While particularly relevant ahead of RESI Europe, the insights apply to any early-stage founder preparing to engage investors. 


CEO Preparation Webinar Series 

LSN Event Partnering Process 

Thursday, January 29 | 10:00 AM ET
Watch the Recording

Attending partnering events plays a key role in fundraising success. This session outlines LSN’s structured approach to outreach strategy, investor targeting, follow-up discipline, and post-event conversion. 


Tips on Pitching 

Tuesday, February 10 | 10:00 AM ET
Watch the Recording

This workshop covers the full pitching lifecycle, from application strategy to live execution and navigating investor-led Q&A. Founders learn how to present risk, differentiation, and value in a way that supports underwriting decisions. 


Branding & Messaging Overview 

Thursday, February 26 | 10:00 AM ET
Sign Up

Founders learn how to align their tagline, elevator pitch, executive summary, tear sheet, and pitch deck so that messaging remains consistent across all investor touchpoints. Learn how to make your messaging stand out among the noise. 


RESI Europe Partnering Tutorial 

Tuesday, March 3 | 10:00 AM ET
Sign Up

A step-by-step walkthrough of the RESI partnering system, including filtering strategies, outreach management, and recommended follow-up processes to maximize conference ROI. 


Investor Webinar: Active Perspectives from Investors and Strategic Partners 

Tuesday, March 10 | 10:00 AM ET
Sign Up

Active investors and strategic partners discuss current capital deployment trends and how early-stage companies are being evaluated in today’s funding environment. 


European Webinar Focus 

From Discovery to Decision: Making Early-Stage Life Science Legible to Capital 

Sessions I–III are part of a dedicated European-focused webinar series designed specifically for companies navigating EU fundraising and cross-border capital engagement. These sessions examine structural translation challenges often faced by European early-stage ventures. 


Session I 

Why Solid Science Fails to Translate Before Capital Even Considers It
Watch the Recording

Explores how promising assets stall before diligence begins and why this is often a translation issue rather than a capital shortage. 


Session II 

Legibility, Signal, and the Real Work Between Seed and Series B
Tuesday, February 24 | 10:00 AM ET / 4:00 PM CET
Sign Up

Examines how signal is formed across scientific, regulatory, and commercial dimensions and what European and global investors require to underwrite risk. 


Session III 

Partnering Is Not Exposure. It Is Filtration
Wednesday, March 4 | 10:00 AM ET / 4:00 PM CET
Sign Up

Analyzes how different partnering environments align with different stages of company development and how founders can avoid engaging the wrong forum too early. 


Preparation as a Strategic Advantage 

Conferences accelerate capital formation. They do not replace preparation. 

The combined CEO Preparation and European-focused webinar tracks reinforce a consistent philosophy: investor engagement is a structured process built on messaging clarity, disciplined partnering, financial readiness, and an understanding of how capital evaluates risk. 

For founders attending RESI Europe, these webinars provide a direct framework for conference preparation. For founders fundraising more broadly, they offer durable guidance that applies well beyond a single event. 

Register for RESI Europe

Confirmed Investors Attending RESI Europe 2026 — Early Bird Rates End Friday 

18 Feb

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation (LSN) is pleased to welcome investors from across the globe to RESI Europe 2026, taking place March 23 in Lisbon, Portugal, with virtual partnering scheduled for March 24–25 and 30–31. This premier event is designed to connect active early-stage investors with innovative life science companies and foster the partnerships that move promising science toward commercialization.

Early Bird rates expire this Friday, and those who register now will save €200. With partnering open March 2, this is the ideal time to secure your place and ensure access to the full RESI Europe experience.

RESI Europe convenes a highly engaged community of venture investors, corporate venture arms, family offices, strategic partners, and non-dilutive funding organizations, all actively evaluating new opportunities across therapeutics, diagnostics, medical devices, and digital health. The event is structured to maximize meaningful interactions, offering curated partnering, targeted networking, and direct visibility into emerging companies seeking capital and strategic collaboration.

For investors focused on sourcing new opportunities, building syndicates, and staying ahead of early-stage innovation trends, RESI Europe provides a concentrated and efficient environment to connect with founders, fellow investors, and ecosystem leaders from Europe, North America, and beyond. Conversations initiated at RESI frequently lead to follow-on diligence, partnerships, and investments that extend well beyond the event itself.

Confirmed RESI Europe Investors

Register before the Early Bird deadline this Friday to secure €200 in savings and confirm your participation alongside a growing global investor community.

Register for RESI Europe